Takeda

This study tests whether a new version of the dengue vaccine works as well as the current approved one. About 500 healthy adults aged 18-60 who have never had dengue will receive two shots three months apart. Researchers will compare immune responses and safety between the two va…

This study tests a drug called TAK-771 in 26 Japanese adults with two rare nerve conditions (CIDP and MMN) that cause weakness and disability. The goal is to see if the drug is safe and helps control symptoms over up to 45 months. Participants receive the drug every 2 to 4 weeks …

This study looks at how safe and effective the drug Entyvio (vedolizumab) is over the long term for people with moderate to severe Crohn's disease. It involves 335 patients who did not get better with other treatments. Researchers will track side effects and how well the drug con…

This study tests an oral medication called TAK-279 in 207 adults with moderate to severe ulcerative colitis. For the first 12 weeks, some participants get the drug and some get a placebo to see if it reduces bowel inflammation and symptoms. After that, everyone can take TAK-279 f…

This study tests two different targeted drugs, ponatinib and imatinib, both combined with low-intensity chemotherapy, in adults newly diagnosed with a specific type of leukemia (Ph+ ALL). The main goal is to see which drug leads to more patients having no detectable cancer cells …

This study looks at how well the drug brigatinib works in adults with a specific type of lung cancer (ALK-positive NSCLC). Researchers will track how long the cancer stays under control and how many patients respond to treatment. About 50 people will take brigatinib as part of th…

This study tracks side effects and how well Revestive (teduglutide) controls symptoms in 250 people with short bowel syndrome. Participants receive injections under the skin as part of their normal care, and doctors monitor them for 36 months. The goal is to better understand the…

This program offers an unapproved drug, fruquintinib, to adults with metastatic colorectal cancer that has worsened after all standard treatments. It is for people who cannot join a clinical trial and have no other options. The goal is to provide access until the drug becomes com…

This study looks at the long-term safety and symptom control of TAKHZYRO (lanadelumab) in 155 people with hereditary angioedema (HAE) in Japan. Participants receive the injection as part of their normal care, and doctors monitor side effects and quality of life for 12 months. The…

This study aimed to see if a combination of drugs could stop the body from attacking a standard Hunter syndrome therapy (ELAPRASE). It was designed for boys who had never received ELAPRASE and were at risk for harmful antibodies. However, the study was withdrawn before any partic…

This study tests a new treatment called TAK-007 in adults with a type of blood cancer called B-cell Non-Hodgkin Lymphoma that has returned or not improved after prior therapy. Participants first receive a short course of chemotherapy to prepare their body, then get one or three d…

This study tests whether TAK-279 can improve symptoms of two rare and severe forms of psoriasis: generalized pustular psoriasis and erythrodermic psoriasis. All 18 adult participants will receive TAK-279 for up to 52 weeks. The main goal is to see how many achieve clear or almost…

This study looks at the long-term safety of a medicine called TAK-881 in adults and children with primary immunodeficiency diseases (PIDD), a condition where the immune system is weak. Participants had already taken part in an earlier study of TAK-881. They will continue receivin…

This study tests whether a daily pill called TAK-788 works better than standard chemotherapy as the first treatment for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). About 354 adults will be randomly assigned to recei…

This study tests whether vedolizumab, given as an IV infusion, can help Chinese adults with moderate to severe ulcerative colitis. About 392 participants will receive either the drug or a placebo to see if it reduces symptoms like diarrhea and bleeding, and helps achieve remissio…

This study is a follow-up for people with Hunter syndrome and cognitive problems who already took part in earlier trials. It aims to check the long-term safety of two drugs given together: idursulfase-IT (injected into the spine) and Elaprase (given through a vein). About 6 child…

This study looks at the long-term safety of a drug called fazirsiran for people with liver disease caused by alpha-1 antitrypsin deficiency. About 31 participants who were in earlier studies will receive fazirsiran every 3 months. Researchers will monitor side effects and check i…

This study looks at how well the drug ixazomib works and what side effects it causes in adults with multiple myeloma who have already tried a different treatment (bortezomib or carfilzomib). About 72 people are taking part. The goal is to see if switching to ixazomib helps contro…

This study tests an oral drug called TAK-788 (mobocertinib) in adults with non-small cell lung cancer. The goal is to find the best dose, check safety, and see if it shrinks tumors. About 334 participants will take the drug daily, with or without chemotherapy, and continue as lon…

This study checks the long-term safety and side effects of the drug TAK-279 in adults with moderate-to-severe plaque psoriasis. About 1,950 participants will take the drug for up to 208 weeks, with regular clinic visits. The goal is to see how well people tolerate the treatment o…

This study tests a new oral drug, Mobocertinib, in Japanese adults with non-small cell lung cancer. The first part finds the safest dose, and the second part checks if the drug shrinks tumors. About 53 people will take part, and they may receive treatment for over a year if it he…

This study looks at 50 people in the UK with hereditary angioedema (HAE) who are starting or have started lanadelumab. Researchers will compare the number of swelling attacks in the year before starting the drug to up to two years after. Data comes from medical records, diaries, …

This study tested a new combination of a targeted drug (brentuximab vedotin) with standard chemotherapy in 59 children and teens with advanced, newly diagnosed Hodgkin lymphoma. The goal was to find the safest dose and see how well the treatment shrinks tumors. Early results sugg…

This study looks at the long-term safety of a medicine called TAK-755 for people with a rare inherited condition that causes dangerous blood clots and bleeding. Participants receive the drug regularly to prevent flare-ups or as needed to treat them. The goal is to see if long-ter…

This study looks at whether a daily medicine called dexlansoprazole can help children aged 2 to 11 who have GERD symptoms like heartburn and stomach pain, but without damage to their esophagus. About 71 children will take the medicine or a placebo for 12 weeks, and parents or the…

This study is a registry that collects information from over 1,300 people with chronic hypoparathyroidism to see how safe and effective the drug rhPTH(1-84) is over time in everyday medical practice. Participants receive their usual care and fill out questionnaires during routine…

This observational study follows about 1,000 people with CD30-positive lymphoma who are already receiving or about to receive brentuximab vedotin as part of their normal care. Researchers will track side effects and how the drug is used in everyday practice. No experimental treat…

This study follows 357 people with multiple myeloma to see how long it takes for the disease to come back after their first treatment. Participants visit their clinic every 3 months for standard care, and researchers track signs of relapse using blood and urine tests. The goal is…

This study looks at health records of about 100 pregnant women with constipation to check if taking prucalopride is safe. Researchers will compare women who took prucalopride, those on other constipation meds, and those on no prescription drugs. The goal is to see if the medicine…

This study is observing over 1,000 adults in Brazil with ulcerative colitis or Crohn's disease who are taking or have taken vedolizumab. Researchers are looking at how long people stay on the treatment and what other therapies they have used. No new treatments are being tested—th…

This study looks at gene changes in tumor samples from 787 people with advanced or recurrent colorectal cancer who took part in an earlier trial. Researchers want to see if certain gene patterns are linked to how long patients lived or how long their cancer stayed under control. …

This study looks at how well a tool called CDPATH™ works in real doctor visits. The tool predicts the chance of serious Crohn's disease problems in the next 3 years. About 200 adults with Crohn's will use the tool to help their doctors choose the best treatment. The goal is to se…

This study looks at genetic markers in tumor tissue to see if they can predict how well two different chemotherapy combinations work for people with advanced colorectal cancer. About 757 patients who have not had chemotherapy before will be randomly assigned to one of two treatme…

This study looks at whether people with Fabry, Gaucher, or Hunter disease are more likely to follow their infusion treatment when it's given at home versus at a hospital. Researchers will review existing data from 222 patients in Mexico to compare treatment adherence and side eff…

This study looks at how long Chinese patients with a specific type of advanced lung cancer (ALK-positive NSCLC) stay on the drug brigatinib when it's their first treatment. Researchers will also track how well the drug controls the cancer over time. The study does not give any ne…